Aspirin versus warfarin in atrial fibrillation: Decision analysis may help patients' choice

Age and Ageing

Volumn 41, Issue 2, 2012, Pages 250-254

  Romero Ortuno, Roman ^a   O'Shea, Diarmuid ^a  

^a ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

Author keywords

Aspirin; Atrial fibrillation; Decision tree analysis; Elderly; Epidemiology; Warfarin

Indexed keywords

ACETYLSALICYLIC ACID; WARFARIN;

ARTICLE; BLEEDING; CONTROLLED STUDY; DRUG USE; HEART ATRIUM FIBRILLATION; HUMAN; MEDICAL DECISION MAKING; PATIENT ATTITUDE; PRIORITY JOURNAL; RISK FACTOR; SCORING SYSTEM; STROKE;

ANTICOAGULANTS; ASPIRIN; ATRIAL FIBRILLATION; DECISION SUPPORT TECHNIQUES; DECISION TREES; HEMORRHAGE; HUMANS; PATIENT SELECTION; PRIMARY PREVENTION; RISK ASSESSMENT; RISK FACTORS; STROKE; TREATMENT OUTCOME; WARFARIN;

EID: 84857219104     PISSN: 00020729     EISSN: 14682834     Source Type: Journal    
DOI: 10.1093/ageing/afr165     Document Type: Article

References (26)

1. Fuster V, Ryden LE, Cannom DS et al. 2011 ACCF/AHA/HRS Focused Updates Incorporated Into the ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in partnership with the European Society of Cardiology and in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. J Am Coll Cardiol 2011; 57: e101-98.
2. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007; 146: 857-67.
3. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 2001; 285: 2864-70.
4. van Walraven C, Hart RG, Wells GA et al. A clinical prediction rule to identify patients with atrial fibrillation and a low risk for stroke while taking aspirin. Arch Intern Med 2003; 163: 936-43.
5. Camm AJ, Kirchhof P, Lip GY et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010; 31: 2369-429.
6. Lip GY, Frison L, Halperin JL, Lane DA. Identifying patients at high risk for stroke despite anticoagulation: a comparison of contemporary stroke risk stratification schemes in an anticoagulated atrial fibrillation cohort. Stroke 2010; 41: 2731-8.
7. Patients with nonvalvular atrial fibrillation at low risk of stroke during treatment with aspirin: Stroke Prevention in Atrial Fibrillation III Study. The SPAF III Writing Committee for the Stroke Prevention in Atrial Fibrillation Investigators. JAMA 1998; 279: 1273-7.
8. Connolly SJ, Eikelboom J, Joyner C et al. Apixaban in patients with atrial fibrillation. N Engl J Med 2011; 364: 806-17.
9. Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 2010; 138: 1093-100.
10. Gage BF, Yan Y, Milligan PE et al. Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF). Am Heart J 2006; 151: 713-9.
11. Hohnloser SH. Stroke prevention versus bleeding risk in atrial fibrillation: a clinical dilemma. J Am Coll Cardiol 2010; 57: 181-3.
12. Man-Son-Hing M, Gage BF, Montgomery AA et al. Preference-based antithrombotic therapy in atrial fibrillation: implications for clinical decision making. Med Decis Making 2005; 25: 548-59.
13. Van Der Velde G. Clinical decision analysis: an alternate, rigorous approach to making clinical decisions and developing treatment recommendations. J Can Chiropr Assoc 2005; 49: 258-63.
14. Zarin DA, Pauker SG. Decision analysis as a basis for medical decision making: the tree of hippocrates. J Med Philos 1984; 9: 181-213.
15. Lip GYH. Implications of the CHA2DS2-VASc and HAS-BLED Scores for thromboprophylaxis in atrial fibrillation. Am J Med 2010; 124: 111-4.
16. Singer DE, Chang Y, Fang MC et al. The net clinical benefit of warfarin anticoagulation in atrial fibrillation. Ann Intern Med 2009; 151: 297-305.
17. Dudley N. Importance of risk communication and decision making in cardiovascular conditions in older patients: a discussion paper. Qual Health Care 2001; 10(Suppl. 1): i19-22.
18. Go AS, Hylek EM, Chang Y et al. Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice?. JAMA 2003; 290: 2685-92.
19. Darkow T, Vanderplas AM, Lew KH, Kim J, Hauch O. Treatment patterns and real-world effectiveness of warfarin in nonvalvular atrial fibrillation within a managed care system. Curr Med Res Opin 2005; 21: 1583-94.
20. Connolly SJ, Pogue J, Eikelboom J et al. Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range. Circulation 2008; 118: 2029-37.
21. Wikipedia. Conditional probability. [cited 2011 16 April]; Available from: http://en.wikipedia.org/wiki/Conditional_probability.
22. Medi C, Hankey GJ, Freedman SB. Stroke risk and antithrombotic strategies in atrial fibrillation. Stroke 2010; 41: 2705-13.
23. Hamlat A, Mazzon A, Adn M et al. Intracranial epidural haematomas in elderly patients: observations in 14 patients. Acta Neurochir (Wien) 2005; 147: 1055-60; discussion 60.
24. Welmerink DB, Longstreth WT Jr, Lyles MF, Fitzpatrick AL. Cognition and the risk of hospitalization for serious falls in the elderly: results from the Cardiovascular Health Study. J Gerontol A Biol Sci Med Sci 2010; 65: 1242-9.
25. Connolly SJ, Ezekowitz MD, Yusuf S et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-51.
26. Eckman MH, Singer DE, Rosand J, Greenberg SM. Moving the tipping point: the decision to anticoagulate patients with atrial fibrillation. Circ Cardiovasc Qual Outcomes 2011; 4: 14-21.